Ecor1 Capital
$2.0B 13F equity value
38 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Ecor1 Capital covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| ZYME | ZYMEWORKS INC | 22,970,388 | $600M | 29.8% |
| ANAB | ANAPTYSBIO INC | 7,880,094 | $532M | 26.4% |
| AKTS | AKTIS ONCOLOGY INC | 4,824,469 | $155M | 7.7% |
| CGON | CG ONCOLOGY INC | 1,494,300 | $106M | 5.3% |
| ETON | ETON PHARMACEUTICALS INC | 2,171,938 | $79M | 3.9% |
| CRSP | CRISPR THERAPEUTICS AG | 1,389,276 | $76M | 3.8% |
| ORIC | ORIC PHARMACEUTICALS INC | 6,728,116 | $73M | 3.6% |
| TRAX | FIRST TRACKS BIOTHERAPEUTICS | 3,174,519 | $64M | 3.2% |
| LKFT | LAKEFRONT BIOTHERAPEUTICS NV | 1,667,119 | $50M | 2.5% |
| NGNE | NEUROGENE INC | 1,271,342 | $40M | 2.0% |
Track Ecor1 Capital's 13F portfolio: $2.0B in reported holdings, 38 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}